Clinical trials: Allergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma
Allergic Rhinitis/Rhinoconjunctivitis +-Intermittent Asthma, Sensitization Against Betula Alba (Birch) Pollen
Depigoid Birch 5000 Longterm Study in Adults and Adolescents
Specific immunotherapy for IgE mediated sensitization to birch pollen. Long-term study to assess safety and efficacy of Depigoid(R)Birch 5000 - a modified pollen extract of Betula alba (Birch) - versus placebo.
- Trial name
- NCT01694836
- Testing
- s.c. injection
- Where
- 2 sites in Germany
- Volunteers
- 634 people
- Sponsor
- Leti Pharma GmbH
Allergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma, Sensitization Against Phleum Pratense Pollen
Dose Finding Study Depigoid Phleum: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
Specific immunotherapy for IgE mediated sensitization to grass pollen 4 concentrations of a modified pollen extract of Phleum pratense are applied to find out the optimum dose.
- Conditions
- Allergic Rhinitis/Rhinoconjunctivitis +- Intermittent Asthma, Sensitization Against Phleum Pratense Pollen, Dose-Finding Study
- Trial name
- NCT01634958
- Testing
- Depigoid Phleum
- Where
- 2 sites in Germany
- Volunteers
- 308 people
- Sponsor
- Leti Pharma GmbH
Allergic Rhinoconjunctivitis
Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch
This study will assess efficacy and safety of intraseasonal specific short-term immunotherapy with Depiquick® Birch in patients with allergic rhinitis and or rhinoconjunctivitis with or without intermittent asthma that have a…
- Trial name
- INSIDE (NCT01902992)
- Testing
- Depiquick Birch (DPG103)
- Where
- 35 sites in Germany
- Volunteers
- 202 people
- Sponsor
- Novartis
Allergic Rhinitis, Rhinoconjunctivitis
Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma
Safety study of Depigoid vaccine Dermatophagoides pteronyssinus or 50% Dermatophagoides pteronyssinus / 50% Dermatophagoides farinae (500 DPP/ml), to treat allergic rhinitis or rhinoconjunctivitis with or without asthma.
- Conditions
- Allergic Rhinitis, Rhinoconjunctivitis, Mild Persistent Asthma, Mild Intermittent Asthma
- Trial name
- NCT01591343
- Testing
- Depigoid® (500 DPP/ml)
- Where
- 10 sites in Spain
- Volunteers
- 8 people
- Sponsor
- Laboratorios Leti, S.L.
Allergic Rhinitis and/or Rhinoconjunctivitis +- Asthma, Immunotherapy, Allergen
Dose Finding Study for Depigoid Birch: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma
Specific immunotherapy for subcutaneous application: Dose finding study to evaluate the correct dose. 4 concentrations of a birch pollen allergen extract are applied in this study. Duration of therapy 20 weeks.
- Trial name
- NCT01144429
- Testing
- Allergoid, allergenic extract of 100% Birch
- Where
- 39 sites in Germany, Lithuania and 1 more
- Volunteers
- 344 people
- Sponsor
- Leti Pharma GmbH